NMN vs Niacin — Trial Data
NMN and Niacin (Vitamin B3 / nicotinic acid) both raise NAD+, through different biochemical pathways, with separate human trial literatures. This page reports the trial evidence behind each, attributed to its source, and clarifies what the 2026 Nature Metabolism NAD+ precursor trial actually compared.
On this page
Mechanism
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required by sirtuin enzymes, PARP (DNA-repair) enzymes, and mitochondrial energy metabolism. It is too large to cross cell membranes efficiently when taken orally, so it is raised via smaller precursor molecules instead.
NMN (nicotinamide mononucleotide) is one biochemical step from NAD+, converted by NMNAT enzymes. Niacin (nicotinic acid) is three steps away, entering via the Preiss-Handler pathway. Christen et al. 2026 (PMID 41540253) additionally reports, from ex vivo fermentation with human microbiota, that gut bacteria convert NR and NMN into nicotinic acid, and that this microbially-produced nicotinic acid is itself a potent NAD+ booster in whole blood — a proposed gut-dependent link between the precursors, though niacin itself was not directly supplemented in that trial.
NMN: Human Trial Evidence
Yoshino et al. 2021 (Science, PMID 33888596) randomized postmenopausal women with prediabetes who were overweight or obese to 10 weeks of oral NMN or placebo, double-blind. Insulin-stimulated glucose disposal (hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling increased with NMN and did not change with placebo. The trial did not measure weight loss or longevity outcomes directly, and enrolled only postmenopausal women with prediabetes.
Yang et al. 2026 (Nutrients, PMID 42514320), a systematic review and meta-analysis of 15 RCTs (10 contributing safety data; doses 250–2,000 mg/day, durations 14 days to 24 weeks), found NMN did not increase overall, serious, withdrawal-related, or system-specific adverse events, and did not significantly elevate liver enzymes (ALT/AST). The same meta-analysis found no significant effect on body weight, BMI, fasting glucose, HbA1c, or lipid profile, with only a slight decrease in diastolic blood pressure and a non-significant downward trend in HOMA-IR.
Niacin: Human Trial Evidence
Niacin's largest modern RCT evidence base comes from its FDA-approved lipid-lowering use, not from a dedicated NAD+-elevation trial. AIM-HIGH (Boden et al. 2011, NEJM, PMID 22085343) randomized 3,414 patients with established cardiovascular disease, already on simvastatin (plus ezetimibe as needed) to maintain LDL 40–80 mg/dL, to extended-release niacin (1,500–2,000 mg/day) or placebo. At 2 years, niacin significantly raised median HDL from 35 to 42 mg/dL, lowered triglycerides from 164 to 122 mg/dL, and lowered LDL from 74 to 62 mg/dL. The trial was stopped after a mean follow-up of 3 years owing to a lack of efficacy: the composite cardiovascular endpoint occurred in 16.4% of the niacin group versus 16.2% of the placebo group (hazard ratio 1.02, 95% CI 0.87–1.21, P=0.79) — no incremental clinical benefit despite the favorable lipid changes.
An earlier trial, the Coronary Drug Project (Canner et al. 1986, PMID 3782631), followed 8,341 men with a prior myocardial infarction and found niacin monotherapy (tested without background statin therapy, which did not yet exist) associated with 11% lower all-cause mortality at 15-year follow-up (52.0% niacin vs. 58.2% placebo, P=0.0004) — a finding that emerged after the original trial ended, not as its primary endpoint. No RCT identified for this page tests niacin specifically as an NAD+-elevation supplement in the way NMN was tested by Yoshino et al. 2021.
| NMN | Niacin | |
|---|---|---|
| Pathway to NAD+ | One biochemical step — converted to NAD+ by NMNAT enzymes | Three-step Preiss-Handler pathway |
| Key human RCT (as an NAD+ precursor) | Yoshino et al. 2021, Science, PMID 33888596 | No RCT of niacin specifically as an NAD+-elevation supplement identified for this page |
| Key human RCT (established use) | Not applicable — NMN has no FDA-approved indication | AIM-HIGH (Boden et al. 2011, NEJM, PMID 22085343) — niacin added to statin therapy for dyslipidemia |
| NAD+-raising evidence | Christen et al. 2026 (PMID 41540253, n=65): NMN raised circulatory NAD+ comparably to NR over 14 days | Not a supplemented arm in Christen et al. 2026; appears only as a microbially-produced metabolite of NR/NMN and in a separate whole-blood experiment |
| Flush side effect | None reported in the cited trials | Yes — flushing (warmth, redness, tingling) is a well-documented effect at therapeutic doses via GPR109A receptor activation |
| Lipid effects (as reported) | Not demonstrated in the trials reviewed for this page | AIM-HIGH: raised median HDL from 35 to 42 mg/dL and lowered LDL from 74 to 62 mg/dL at 2 years vs. placebo, added to statin therapy |
| Cardiovascular outcome (as reported) | No cardiovascular-outcomes trial of NMN identified for this page | AIM-HIGH: no reduction in the composite cardiovascular endpoint despite the lipid changes (16.4% niacin vs. 16.2% placebo, HR 1.02, P=0.79); trial stopped early for lack of efficacy |
| Regulatory status | Sold as a dietary supplement in the US; not FDA-approved as a drug | FDA-approved as a prescription drug for dyslipidemia at higher doses; also sold as an over-the-counter supplement |
The 2026 Nature Metabolism Trial
Christen et al. 2026 (Nat Metab, PMID 41540253, NCT05517122) is a real, published trial — a randomized, open-label (not double-blind), placebo-controlled study in 65 healthy participants, comparing 14 days of nicotinamide riboside (NR), NMN, or nicotinamide (Nam) against placebo. It did not include niacin (nicotinic acid) as a supplemented arm.
Result: NR and NMN comparably increased circulatory NAD+ concentrations over the 14-day course. Nicotinamide did not produce the same sustained increase — it acutely and transiently affected the whole-blood NAD+ metabolome instead. Using ex vivo fermentation with human gut microbiota, the researchers found that NR and NMN give rise to nicotinic acid (niacin) via microbial conversion, and separately showed in whole blood that nicotinic acid — not NMN, NR, or nicotinamide — is a potent direct NAD+ booster.
A prior version of this page described a “2026 head-to-head…trial in Nature Metabolism” that found “NMN and NR comparable in raising blood NAD+ levels” without a DOI or link. That description of NMN and NR is accurate and matches Christen et al. 2026 — but the trial did not test niacin directly, so it does not support a claim about NMN versus niacin specifically. The full three-way breakdown of NMN, NR, and niacin is on the separate NMN vs NR vs Niacin page.
Adverse Events
NMN: Yang et al. 2026 (PMID 42514320) found no increase in overall, serious, withdrawal-related, or system-specific adverse events across 10 trials contributing safety data (doses 250–2,000 mg/day, up to 24 weeks), and no significant elevation of liver enzymes.
Niacin: flushing (warmth, redness, tingling) is a well-documented effect at therapeutic doses, mediated by GPR109A receptor activation and prostaglandin release; it typically begins 15–30 minutes after dosing and decreases with consistent use as receptors desensitize. At the higher doses used in AIM-HIGH (PMID 22085343) for its cardiovascular/lipid indication, niacin carries a documented risk of liver-enzyme elevation, particularly with extended-release formulations.
Evidence Level
NMN: Human RCT (Yoshino et al. 2021, PMID 33888596, double-blind, single population) plus a 15-trial safety meta-analysis (Yang et al. 2026, PMID 42514320). Niacin: Human RCT for its cardiovascular/lipid indication (AIM-HIGH, PMID 22085343; Coronary Drug Project, PMID 3782631); no RCT specifically testing niacin as an NAD+-elevation supplement was identified for this page. The three-precursor comparison (Christen et al. 2026, PMID 41540253) is Human RCT but open-label, not double-blind, and did not supplement niacin directly.
The NMN and niacin trials cited above enrolled different populations (postmenopausal prediabetic women vs. patients with established cardiovascular disease on statin therapy) for different purposes (insulin sensitivity vs. secondary cardiovascular prevention) over different durations. They are not head-to-head comparisons, and no RCT identified for this page randomizes participants to NMN against niacin for NAD+ elevation specifically.
FAQ
What does the NMN human trial evidence show?
Yoshino et al. 2021 (Science, PMID 33888596) randomized postmenopausal women with prediabetes who were overweight or obese to 10 weeks of oral NMN or placebo, double-blind. NMN increased insulin-stimulated glucose disposal (measured by hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling; placebo produced no change. This is one trial in one population and does not establish effects in men or in metabolically healthy adults. A 2026 safety meta-analysis (Yang et al., Nutrients, PMID 42514320; 15 trials, doses 250–2,000 mg/day) found NMN did not increase adverse events or liver-enzyme elevation, though it also found no significant effect on body weight, fasting glucose, HbA1c, or lipid profile across the pooled trials.
Is there a real 2026 head-to-head trial, and did it include niacin?
Yes, a real trial exists — but it did not compare NMN against niacin. Christen et al. 2026 (Nat Metab, PMID 41540253, NCT05517122) randomized 65 healthy participants to 14 days of nicotinamide riboside (NR), NMN, nicotinamide (Nam), or placebo, open-label. NR and NMN comparably raised circulatory NAD+; nicotinamide produced only a transient effect. Niacin (nicotinic acid) was not a supplemented arm — it appeared only as a microbial-conversion product of NR and NMN in an ex vivo gut-fermentation experiment, and separately as a potent NAD+ booster in a whole-blood experiment. A prior version of this page described a “2026 head-to-head…trial in Nature Metabolism” comparing NMN and NR without a citation; the real trial is Christen et al. 2026, and it is reported accurately here as an NMN-vs-NR-vs-nicotinamide comparison, not an NMN-vs-niacin comparison. See also the separate NMN vs NR vs Niacin comparison page for the full three-way breakdown of that trial.
What does the niacin trial evidence show?
Niacin's largest modern RCT evidence comes from its lipid-lowering use, not from NAD+-elevation trials. AIM-HIGH (Boden et al. 2011, NEJM, PMID 22085343) randomized 3,414 patients with cardiovascular disease already on statin therapy to extended-release niacin (1,500–2,000 mg/day) or placebo. At 2 years, niacin raised median HDL from 35 to 42 mg/dL, lowered triglycerides from 164 to 122 mg/dL, and lowered LDL from 74 to 62 mg/dL — but the trial was stopped early after a mean 3-year follow-up because there was no reduction in the composite cardiovascular endpoint (16.4% niacin vs. 16.2% placebo, hazard ratio 1.02, P=0.79). An earlier trial, the Coronary Drug Project (Canner et al. 1986, PMID 3782631), found niacin monotherapy (without background statin therapy) associated with 11% lower all-cause mortality at 15-year follow-up (52.0% vs. 58.2%, P=0.0004), though this was a late, post-trial mortality finding rather than the primary endpoint. No RCT identified for this page tested niacin specifically as an NAD+-elevation supplement.
What NMN and niacin doses were used in these trials?
Yang et al. 2026's NMN safety meta-analysis (PMID 42514320) pooled trials using 250–2,000 mg/day. AIM-HIGH (PMID 22085343) used extended-release niacin at 1,500–2,000 mg/day for its cardiovascular/lipid indication. A prior version of this page stated “250–500mg daily” for NMN and “500–1500mg daily” for niacin without citing a source; those ranges are replaced here with the doses actually used in the cited trials, which run somewhat higher for both compounds.
Does niacin's flushing side effect show up in trial data?
Niacin (nicotinic acid) activates GPR109A receptors on skin cells, triggering prostaglandin release that dilates blood vessels and produces warmth, redness, and tingling — a well-characterized pharmacological effect distinct from the NAD+-precursor trials cited above, neither of which reported flushing with NMN.
References
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. https://pubmed.ncbi.nlm.nih.gov/42514320/
- Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8(1):62-73. https://pubmed.ncbi.nlm.nih.gov/41540253/
- AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-2267. Correction: N Engl J Med 2012;367(2):189 (no PMID). https://pubmed.ncbi.nlm.nih.gov/22085343/
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255. https://pubmed.ncbi.nlm.nih.gov/3782631/
Have a question about NMN vs Niacin — Trial Data? Send us an email